(pirbuterol acetate inhalation aerosol)
The active component of MAXAIR AUTOHALER is pirbuterol acetate, a beta-2 adrenergic bronchodilator.
MAXAIR AUTOHALER is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma. It may be used with or without concurrent theophylline and/or corticosteroid therapy.
Published Studies Related to Maxair (Pirbuterol)
Comparison of the Maxair Autohaler to wet nebulizer in patients with acute asthma. [1998.09]
STUDY OBJECTIVE: Patients with acute asthma often have difficulty using a conventional metered-dose inhaler. The Maxair Autohaler (3M Pharmaceuticals; St. Paul, MN) is a hand-held breath-actuated device developed to help patients coordinate drug administration. The study objective is to compare the efficacy of the Autohaler with inhaled beta-agonist administered by wet nebulizer in treating acute asthma exacerbations... CONCLUSION: In patients with moderate asthma exacerbations, similar improvements in pulmonary function are obtained when beta-agonists are given by either the Maxair Autohaler or a wet nebulizer device.
Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. [1995.01]
BACKGROUND: Although both beta-adrenergic agonists and anticholinergic agents are widely used in the treatment of patients with COPD, they influence the pulmonary circulation and ventilation differently. We compared the effects of these two agents on gas exchange and distribution of ventilation in COPD... CONCLUSION: Pirbuterol and ipratropium are equally effective bronchodilators in COPD. Pirbuterol results in a significant rise in P(A-a)O2 and resting VE. Ipratropium does not affect these measurements and seems to reduce the oxygen cost of breathing. The results suggest significant differences between the effects of the two agents on gas exchange, ventilation, and VO2 which could be of clinical significance.
Double-blind, clinical efficacy study comparing 400 micrograms of pirbuterol versus placebo delivered by a breath-actuated aerosol inhaler. 
Pirbuterol is a selective beta-2 adrenergic agonist that is indicated for the treatment of bronchospasm in patients with asthma... Therefore, we feel that pirbuterol administered through the BAA device is a safe, effective means of treating both acute and chronic asthma.
Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. [1991.05]
In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma. Each child was randomized to both treatments with a washout period of at least 1 day and at most 13 days...
A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol. [1990.06.13]
In this double blind study, the cardiovascular and hypokalaemic effects of equal doses of inhaled pirbuterol and salbutamol were compared in eight healthy volunteers. Increasing doses of 200, 400, 600 and 800 micrograms (total dose 2000 micrograms) were given from a metered dose inhaler at 15 min intervals, followed by measurement of heart rate, blood pressure, total electromechanical systole (QS2I) (as a measure of inotropic response) and plasma potassium (K+) concentration 15 min after each inhalation...
Clinical Trials Related to Maxair (Pirbuterol)
A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma [Completed]
Reports of Suspected Maxair (Pirbuterol) Side Effects
Chronic Obstructive Pulmonary Disease (4),
Chest Pain (2),
Device Malfunction (2),
Chest Discomfort (2),
Condition Aggravated (2),
Dyspnoea Exertional (1),
Haematocrit Decreased (1), more >>
Page last updated: 2006-01-31